The USPTO should be lauded for the way it has responded to the growing health crisis but, as the former commissioner for patents Bob Stoll points out, stakeholders could see a drop-off in activity among examiners at the end of the year
The USPTO should be lauded for the way it has responded to the growing health crisis but, as the former commissioner for patents Bob Stoll points out, stakeholders could see a drop-off in activity among examiners at the end of the year